La vendita allo scoperto per Vivos dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Vivos. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Vivos (OTC:RDGL) Azioni, Report sulle vendite allo scoperto

Vivos Inc is a radiation oncology medical device company. It is engaged in the development of RadioGel which is a brachytherapy device comprising highly insoluble particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors. IsoPet is another product of the company used for the treatment of solid tumors in animals. The company derives revenue through sales of its products.

Vivos Inc

A new Seattle-based <a href="https://www.benzinga.com/25/05/45444616/capital-connect-crumbles-jpmorgans-175m-bet-on-startup-platform-ends-amidst-venture-capital-market-turmoil">startup</a>, Hearvana, is making waves in the audio technology industry. Founded by University of Washington computer science professor Shyam Gollakota and PhD student Malek Itani, Hearvana is developing superhuman hearing capabilities for everyday devices. These advancements are poised to be integrated into billions of earbuds, hearing aids, and smartphones, according to<a href="https://www.geekwire.com/2025/ai-startup-led-by-uw-computer-science-whiz-enables-superhuman-hearing-capabilities/"> GeekWire</a>.
The company is being incubated by the AI2 Incubator, part of the Allen Institute for AI, which was founded by <a href="https://www.benzinga.com/25/04/44831264/microsoft-debuts-computer-use-tool-for-copilot-studio-ceo-satya-nadella-says-anyone-can-build-agents-that-take-action-on-the-ui-across-desktop-and-web-apps">Microsoft</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) co-founder Paul Allen. The incubator was launched by AI2's founding CEO Oren Etzioni to support early-stage AI startups, according to the institute&#8217;s <a href="https://www.ai2incubator.com/team">website</a>. The company aims to use artificial intelligence to make hearing seamless, personalized, and radically more powerful for billions of users, GeekWire reports.
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
Gollakota told GeekWire that Hearvana is &#8220;creating AI breakthroughs that are shaping the future of sound,&#8221; adding that their &#8220;AI algorithms enable on-device superhuman hearing capabilities and will be part of billions of earbuds, hearing aids, and smartphones.&#8221;
<h2 class="wp-block-heading">A Sound Bubble That Lets You Choose What You Hear</h2>
Hearvana's technology focuses on real-time audio filtering, letting users choose what they want to hear while blocking out everything else. According to GeekWire, the company's AI can locate sound sources, understand their distance, and build what Gollakota and his team describe as a "sound bubble."
This innovation solves a pain point nearly everyone experiences, trying to follow a conversation in a noisy restaurant or crowded event. The algorithms run directly on a device, meaning no data needs to be sent to the cloud, GeekWire reports.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a>
Hearvana&#8217;s early research,<a href="https://www.sciencedaily.com/releases/2024/11/241114161302.htm"> published</a> in November by Gollakota and Itani, demonstrated headphones that adjust dynamically to noise and user focus. The team believes this approach could soon set the standard in next-generation audio technology, aligning with the broader professional audiovisual market, which is projected to reach $422 billion globally by 2029, according to<a href="https://www.avixa.org/about-us/press-room/2024/08/21/pro-av-revenue-forecast-to-reach--422-billion-by-2029--according-to-new-research-from-avixa"> AVIXA&#8217;s 2024 Industry Outlook and Trends Analysis</a>.
<h2 class="wp-block-heading">Google, Meta, And AI2: A Deep Bench Of Innovation</h2>
Hearvana's founding team blends academic excellence with real-world traction. Gollakota is no stranger to startup success. According to GeekWire, he previously co-founded Sound Life Sciences, which developed smartphone-based breathing detection and was acquired by Google in 2022. He also co-founded Wavely Diagnostics, a smartphone app that detects ear infections.
The startup&#8217;s team brings together expertise from academia and industry. Itani, who previously interned at Meta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), worked on smart glasses during his time at the tech giant, GeekWire reports. The team's work has already drawn support from Oren Etzioni, technical director at AI2 Incubator.
See Also: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a>
&#8220;Hearvana is my favorite kind of startup,&#8221; Etzioni told GeekWire. &#8220;It addresses a familiar pain point — we all struggle to hear in noisy settings like a restaurant or a party — with deep AI technology.&#8221;
Hearvana is also actively hiring as it gears up to scale its impact. In a recent<a href="https://www.linkedin.com/posts/shyam-gollakota-84b8541_hearvanaai-hiring-activity-7191709830827481088-7ytr"> LinkedIn post</a>, Gollakota announced the company is looking for passionate candidates to help shape "the future of sound." The startup is currently recruiting for two key roles: a founding deep learning engineer and a founding acoustic simulation engineer.
As Hearvana continues to develop its technology, the company may make significant contributions to the field of audio processing. By combining cutting-edge AI with practical applications, Hearvana aims to enhance the auditory experience for users worldwide.
Read Next:
<ul class="wp-block-list">
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
Image: Shutterstock

News

MSFT

Seattle's AI2-Backed Hearvana Launches Superhuman Hearing Capabilities For Billions Of Devices, Created By Google-Acquired Innovator

Loews (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/L#NYSE">L</a>) has outperformed the market over the past 5 years by 7.24% on an annualized basis producing an average annual return of 21.53%. Currently, Loews has a market capitalization of $18.37 billion. 
Buying $100 In L: If an investor had bought $100 of L stock 5 years ago, it would be worth $265.10 today based on a price of $87.59 for L at the time of writing.
<h3>Loews's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747954832_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Loews Stock In The Last 5 Years

The U.S. economy faces a growing list of headwinds that could threaten growth and stability in 2025. Persistent tariff pressures, rising borrowing costs, low consumer confidence and the resumption of student loan payments each has the potential to slow growth and <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45564489/trumps-big-tax-bill-clears-the-house-30-year-yields-jump-to-515-as-bond-market-freaks">disrupt economic stability.&nbsp;</a>
Here are 10 key downside risks Dr. Torsten Slok, chief economist for Apollo Global, <a href="https://www.apolloacademy.com/10-downside-risks-to-the-us-economic-outlook/">identified this week</a>. 
1. Moody's Downgrade Raises Borrowing Cost
<ul class="wp-block-list">
<li>Last week, Moody's cut the U.S. long-term credit rating<a href="https://www.benzinga.com/news/econ-s/25/05/45479078/moodys-downgrades-us-credit-rating-over-debt-deficit-concerns"> from Aaa to Aa1</a>, which made borrowing more expensive for consumers and businesses and put pressure on spending and investment.</li>
</ul>
2. Weakening Housing Demand
<ul class="wp-block-list">
<li>Higher mortgage rates are dampening <a href="https://www.benzinga.com/government/regulations/25/05/45540541/5-treasury-yields-are-back-and-so-are-painful-mortgage-rates">demand for homes</a> and slowing down one of the U.S. economy's key growth engines.&nbsp;</li>
</ul>
Read Next: <a href="https://www.benzinga.com/news/legal/25/05/45568107/solar-energy-stocks-drop-as-house-approves-major-rollback-of-climate-incentives?utm_source=article">Solar Energy Stocks Drop As House Approves Major Rollback Of Climate Incentives</a>
3. Tariffs Cutting into Corporate Earnings
<ul class="wp-block-list">
<li>President Donald Trump recently reduced many of the originally steep tariffs he announced on "Liberation Day," but the average tariff rate remains elevated. The higher levies are squeezing company profits, especially for firms reliant on imported goods and global supply chains.&nbsp;</li>
</ul>
4. Trade Deal Uncertainty and Retaliation Risk
<ul class="wp-block-list">
<li>Though most reciprocal tariffs have been "paused" and reduced to a baseline of 10% for 90 days to allow for negotiations, few permanent deals have been reached. China and the U.S. would have to agree on a more permanent solution soon as the pause is set to expire in mid-August.&nbsp;</li>
</ul>
5. High Uncertainty Weakening Corporate Confidence
<ul class="wp-block-list">
<li>Businesses are facing extreme uncertainty, making it difficult to plan and invest, which could slow economic activity. JPMorgan CEO Jamie Dimon said businesses are in &#8220;wait and see&#8221; mode and are postponing hiring, expansions and M&amp;A deals while<a href="https://www.benzinga.com/news/management/25/04/44774273/jpmorgan-ceo-jamie-dimon-expects-sp-500-growth-forecast-to-be-cut"> the future remains</a> uncertain. </li>
</ul>
&#8220;People have to adjust to this new environment,&#8221; Dimon said.&nbsp;
6. Consumer Spending Hit by Higher Prices
<ul class="wp-block-list">
<li>Rising prices at retailers are causing consumers to cut back on spending. Walmart CEO Doug McMillon told analysts on the <a href="https://www.benzinga.com/news/management/25/05/45473067/walmart-prices-will-rise-within-weeks-as-trump-tariffs-drive-up-costs-will-other-retailers-follow-suit">company's earnings call</a> on Thursday that the retailer will be raising prices on some items as a direct result of ongoing tariffs.&nbsp;</li>
</ul>
Read Next: <a href="https://www.benzinga.com/news/rumors/25/05/45555558/wolfspeed-stock-plunges-59-on-bankruptcy-fears-options-traders-cash-in?utm_source=article">Wolfspeed Stock Plunges 59% On Bankruptcy Fears: Options Traders Cash In</a>
7. Historically Weak Consumer Confidence
<ul class="wp-block-list">
<li>Consumer sentiment is dropping drastically and raising concerns about future demand and economic resilience. The University of Michigan's May consumer survey showed that sentiment among American consumers has plunged <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45470155/consumer-sentiment-crashes-to-5-year-lows-as-inflation-fears-reach-1981-levels">to the lowest levels</a> since June 2020, while expectations for inflation surged to heights last seen in the early 1980s.</li>
</ul>
8. Lower Tourism
<ul class="wp-block-list">
<li>A decline in visitor arrivals from key regions is negatively impacting airlines, hotels and restaurants, according to the Apollo economist.&nbsp;</li>
</ul>
9. Student Loan Payments Restarting
<ul class="wp-block-list">
<li>The end of the COVID-19 pandemic-era pause on student loan payments is expected to strain household budgets and reduce discretionary spending. The U.S. Department of Education resumed collections on defaulted <a href="https://www.benzinga.com/25/04/45012792/trump-administration-to-resume-collections-on-student-loans-5-million-borrowers-in-default">federal student loans</a> in May, and according to data from the DOE, more than five million borrowers are in default. </li>
</ul>
10. DOGE Government Worker Layoffs
<ul class="wp-block-list">
<li>Layoffs of federal employees and contractors could lead to higher unemployment and reduced consumer spending, with ripple effects across the economy, according to Dr. Slok.&nbsp;</li>
</ul>
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45378427/trump-wants-to-kickstart-nuclear-development-these-5-stocks-could-boom?utm_source=articleShare">Trump Wants To Kickstart Nuclear Development: These 5 Stocks Could Boom</a>&nbsp;</li>
</ul>
Photo: Shutterstock

Global

Economics

10 Risks To America's Economic Future: High Prices, Housing Woes, Student Loans And More

OR Royalties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OR#NYSE">OR</a>) has outperformed the market over the past 5 years by 6.38% on an annualized basis producing an average annual return of 20.66%. Currently, OR Royalties has a market capitalization of $4.68 billion. 
Buying $100 In OR: If an investor had bought $100 of OR stock 5 years ago, it would be worth $255.76 today based on a price of $24.99 for OR at the time of writing.
<h3>OR Royalties's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747953929_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning OR Royalties Stock In The Last 5 Years

Billionaire investor Bill Ackman's hedge fund, Pershing Square Capital Management, established a new position in Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) after the stock dropped more than 30% <a href="https://www.benzinga.com/25/05/45372179/us-china-tariff-truce-adds-nearly-45-billion-to-net-worth-of-elon-musk-jeff-bezos-mark-zuckerberg">earlier this year. </a>
The Details: Pershing Square chief investment officer Ryan Israel told analysts on a call Thursday that the firm acquired Amazon shares at an "extremely attractive" price, according to a Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-05-22/pershing-square-buys-amazon-stake-after-31-drop-in-stock-price?embedded-checkout=true">report</a>.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/legal/25/05/45568107/solar-energy-stocks-drop-as-house-approves-major-rollback-of-climate-incentives?utm_source=article">Solar Energy Stocks Drop As House Approves Major Rollback Of Climate Incentives</a>
"This was a uniquely attractive time as we felt that the company would be able to work through any slowdown" in Amazon's cloud business, Israel said.
He added that Amazon is a "fantastic franchise"&nbsp; and "well on its way" to delivering more than 20% earnings per share growth.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Amazon stock tumbled more than 30% following President Donald Trump's tariff announcements on "Liberation Day" in early April to a low of $167.32 on April 21.&nbsp;
Amazon CEO Andy Jassy told shareholders on Wednesday that the company <a href="https://www.benzinga.com/news/management/25/05/45551594/amazon-ceo-andy-jassy-no-slowdown-in-consumer-spending-amid-tariffs">has not experienced</a> any significant changes in consumer spending due to the tariffs.&nbsp;
Jassy said, "We have not seen any attenuation of demand at this point," and added that there have been no "meaningful average selling price increases."&nbsp;
AMZN Stock Price Action: Amazon shares ended Thursday's session up 0.98% at $203.10, according to data from<a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw"> Benzinga Pro</a>.&nbsp;
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/rumors/25/05/45555558/wolfspeed-stock-plunges-59-on-bankruptcy-fears-options-traders-cash-in?utm_source=article">Wolfspeed Stock Plunges 59% On Bankruptcy Fears: Options Traders Cash In</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Large Cap

Hedge Funds

Movers

Tech

AMZN

Bill Ackman's Pershing Square Builds New Stake In Amazon At 'Extremely Attractive' Price

Jamie Dimon says the U.S. can&#8217;t take its status as the world&#8217;s top economic power for granted anymore.
In a recent interview with <a href="https://www.youtube.com/watch?v=xCSFDihV51g">Bloomberg Television</a>, the JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) CEO was asked whether he worries about U.S. supremacy and exceptionalism. He answered, perhaps surprisingly, that he never quite believed in American exceptionalism and warned that regulation and what he called &#8220;stupid bureaucracy&#8221; are holding the country back.
<h2 class="wp-block-heading">Dimon Says U.S. Risks Falling Behind</h2>
&#8220;We've slowed ourselves down with regulation, stupid bureaucracy,&#8221; Dimon said. &#8220;We haven't done budgets in years. So, no, we shouldn't assume it's forever.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
He pointed to a long list of issues that are weighing on the economy: inflation, deficits, rising interest rates, and ongoing global conflicts.
&#8220;There&#8217;s a lot of uncertainty out there that you can&#8217;t discount,&#8221; he said, mentioning the war in Ukraine, terrorism, instability in the Middle East and U.S. deficits. He also highlighted the risks created by tariffs, saying that although the U.S. has backed off some of its earlier moves, even the current level of trade tension is causing companies to hesitate.
&#8220;Even at this level, you see people holding back on investment and thinking through what they want to do,&#8221; Dimon said.
On the <a href="https://www.benzinga.com/25/04/45071155/mild-recession-is-best-case-outcome-jpmorgan-ceo-jamie-dimon">possibility of a U.S. recession</a>, Dimon didn&#8217;t give a firm prediction. Instead, he deferred to economists and put the chances at &#8220;about 50%.&#8221; Interestingly, JPMorgan&#8217;s analysts raised their <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44645681/jpmorgan-raises-recession-risk-to-60-as-largest-us-tax-hike-in-60-years-hits-global-economy">recession probability to 60%</a> in April, up from 40% in March.&nbsp;
He added, &#8220;All these things are probably inflationary&#8230; and slowing down the economy.&#8221;
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a>
<h2 class="wp-block-heading">Is America a Bad Investment Destination?&nbsp;</h2>
Still, despite the challenges, Dimon said America remains the top choice for investment: &#8220;If you would take all of your money and put it in one country, it would still be America.&#8221;
However, he cautioned that this dominance isn't guaranteed. "You do not have a divine right to success,&#8221; he said. &#8220;If we don't do everything right, we can lose that.&#8221;
Dimon also expressed admiration for some foreign leaders who he believes are taking a more business-friendly approach. He praised French President Emmanuel Macron, U.K.&nbsp; Prime Minister Keir Starmer and German Chancellor Friedrich Merz for their pro-business attitudes. &#8220;I think Macron is one of the best political leaders on the planet today.&#8221;
On global competition, Dimon was frank: &#8220;Assume competition. Assume they&#8217;re coming at you in every angle.&#8221;
See Also: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a>
Asked about <a href="https://www.benzinga.com/markets/25/05/45336194/charlie-mungers-timeless-advice-for-navigating-volatile-markets-be-fearful-when-others-are-greedy-and-be-greedy-when-others-are-fearful">market volatility</a>, Dimon said he expects it to continue and warned against assuming it will go away anytime soon.
&#8220;I think it&#8217;s a mistake to think we can go through all the things we&#8217;re going through and the volatility itself will come down,&#8221; he said.
As for JPMorgan&#8217;s <a href="https://www.benzinga.com/news/25/05/45483359/jamie-dimon-says-dont-tell-jpmorgan-what-to-do-as-he-tells-remote-workers-you-cant-learn-working-fro">return-to-office policy</a>, which drew <a href="https://www.benzinga.com/markets/equities/25/02/43757032/jamie-dimon-goes-off-on-return-to-office-critics-you-dont-have-to-work-at-jpmorgan">media attention</a> earlier this year, Dimon stood firm: &#8220;I&#8217;m not against work from home. I&#8217;m against work when it doesn&#8217;t work.&#8221;
He said the company has seen no additional attrition and that young employees especially need in-person experience to grow.
&#8220;It&#8217;s an apprenticeship system and you can&#8217;t learn working from your basement,&#8221; Dimon said.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
Image: Shutterstock

Jamie Dimon Says He Never Bought Into American Exceptionalism. He Blames Regulation And 'Stupid Bureaucracy' For Slowing The Country Down

GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) has outperformed the market over the past 5 years by 32.45% on an annualized basis producing an average annual return of 46.73%. Currently, GE Aerospace has a market capitalization of $245.91 billion. 
Buying $1000 In GE: If an investor had bought $1000 of GE stock 5 years ago, it would be worth $6,801.53 today based on a price of $230.60 for GE at the time of writing.
<h3>GE Aerospace's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747953021_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In GE Aerospace 5 Years Ago Would Be Worth Today

WIIM

IMMX

IMMX stock has given up its prior gain. Immix Biopharma shares were trading higher after the company announced the publication of cell therapy NXC-201 Abstract #7508, selected for oral presentation at the 2025 American Society of Clinical Oncology Annual Meeting.

In a world where the go-to buzzword is &#8220;disruption,&#8221; <a href="https://www.benzinga.com/etfs">one new ETF </a>is doubling down on the established players. 
Strategy Shares, in conjunction with Rareview Capital LLC, debuted the Monopoly ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/MPLY#BATS">MPLY</a>) on May 16, a thematic fund focused on firms with deep market roots, or to use the parlance of the fund, &#8220;monopolistic attributes.&#8221;
Since its launch, the fund&#8217;s offering has been hit with a mix of curiosity and goal-oriented focus. Whereas most money is pursuing innovation, growth-at-all-costs, or the next breakout theme, MPLY pursues safety in dominance instead. 
Its investment thesis relies on four characteristic attributes: • Established brand dominance • Regulatory exclusivity • High entry barriers • No direct competition or limited direct competition. 
That is to say, businesses that don&#8217;t merely compete but effectively set the rules of the game.
Also Read: <a href="https://www.benzinga.com/etfs/new-etfs/25/05/45574609/palantir-among-key-picks-as-blackrock-launches-active-defense-industrials-etf">Palantir Among Key Picks As BlackRock Launches Active Defense Industrials ETF</a>
<h1 class="wp-block-heading">Structure And Strategy</h1>
MPLY will have 75 to 125 holdings, diversified among sectors and sizes, with some degree of diversification despite focusing on monopolistic characteristics. Per the guidelines of the fund, the portfolio will not include regulated utilities, presumably a tip of the hat to the avoidance of price-control-subject sectors that may limit returns regardless of monopolistic market position.
<h1 class="wp-block-heading">A Defensive Play In A Volatile Market</h1>
Rareview Capital CIO Neil Azous highlighted the fund&#8217;s possible status as a &#8220;core solution&#8221; within equity portfolios. 
&#8220;MPLY can be a core solution and a potential replacement for a portion of a portfolio's stock market exposure. The Fund seeks to capture market upside, but may act more defensive on the downside,&#8221; Azous said. 
&#8220;The companies the fund invests in generally have sustainable competitive advantages, tangible barriers to entry, and defensive earnings streams. As a result, they typically have the potential to generate high returns on invested capital that may compound over long periods,&#8221; Azous added. 
That means the type of reliability investors seek amid uncertainty in markets: high returns on capital, compounded over time.
Essentially, MPLY is not merely about market dominance, it&#8217;s about foresight in an increasingly story-oriented market. By focusing on long-term moats instead of short-term momentum, the fund offers a defensive growth approach that might appeal to institutional investors as well as individual investors hesitant to overexpose themselves to story stocks.
<h1 class="wp-block-heading">Beyond The Buzz</h1>
While the marketing of the fund emphasizes a compelling mix of defense and innovation, invoking &#8220;Monopoly&#8221; as a branding gimmick is interesting. The label brings to mind the classic board game, as well as a genuine economic entity, so exposed to regulators. Still, the managers are sensitive to delineate their holdings as companies with &#8220;monopolistic qualities,&#8221; but not as so-called monopolies, a semantic, but possibly regulatory, distinction.
The true test will come in the doing: whether MPLY can balance its audacious thesis with strong performance through market cycles. For now, it presents a sharp proposition, betting not on something trendy and new, but on something big that is already dominating the board.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/05/45574690/nvidia-amd-and-the-ai-arms-race-3-explosive-etfs-to-watch-right-now">Nvidia, AMD And The AI Arms Race: 3 Explosive ETFs To Watch Right Now</a></li>
</ul>
Photo: Shutterstock

New ETFs

ETFs

MPLY

Strategy Shares Rolls The Dice With Monopoly ETF For Market Giants

CenterPoint Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNP#NYSE">CNP</a>) has outperformed the market over the past 5 years by 1.97% on an annualized basis producing an average annual return of 16.25%. Currently, CenterPoint Energy has a market capitalization of $24.24 billion. 
Buying $100 In CNP: If an investor had bought $100 of CNP stock 5 years ago, it would be worth $212.35 today based on a price of $37.14 for CNP at the time of writing.
<h3>CenterPoint Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747952112_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In CenterPoint Energy 5 Years Ago Would Be Worth Today

Heritage Commerce Corp (NASDAQ:<a href="https://www.benzinga.com/stock/HTBK#NASDAQ">HTBK</a>) ("Heritage" or "Company"), parent company of Heritage Bank of Commerce (the "Bank"), a premier community business bank, today announces the appointment of Julianne Biagini-Komas as Chair of the Board of Directors (the "Board"), replacing Chairman Jack W. Conner who has assumed the role of Chair Emeritus and has indicated he intends to remain on the Board to provide a smooth and orderly transition through October 2025. Ms. Biagini-Komas, a Certified Public Accountant, has served as Vice Chair of the Board since October 2024, as a director since 2014 and as the Chair of the Audit Committee since 2020.

Management

HTBK

Heritage Commerce Corp Appoints Julianne Biagini-Komas As New Chair Of The Board, Succeeding Jack W. Conner

Nuveen Arizona Dividend Advantage Municipal Funds 3

OKLO

Shares of nuclear-linked stocks are trading higher amid report that President Trump to sign orders to boost nuclear power as soon as Friday.

KBR(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBR#NYSE">KBR</a>), a leader in human spaceflight expertise for more than 60 years, has signed a letter of intent with ACMI Properties to grow KBR's commercial space capabilities including a human spaceflight food laboratory at NASA's Exploration Park, adjacent to Johnson Space Center. The 45,000 square-foot, Houston-based facility would serve the growing commercial low-Earth orbit (LEO) industry where tailorable astronaut food systems and solutions will be designed, tested, validated, produced, and integrated into customer mission environments.

Contracts

KBR Signs LOI With ACMI Properties To Expand Commercial Space Capabilities With New Human Spaceflight Food Laboratory At NASA's Exploration Park Near Johnson Space Center

In the last three months, 37 analysts have published ratings on NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">19</td>
<td align="right">13</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">11</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated NVIDIA and provided 12-month price targets. The average target is $172.3, accompanied by a high estimate of $220.00 and a low estimate of $100.00. Experiencing a 3.85% decline, the current average is now lower than the previous average price target of $179.19. 
<img src="https://www.benzinga.com/files/images/story/2025/1747951279_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of NVIDIA by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt Bryson</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$160.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$175.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Jay Goldberg</td>
<td>Seaport Global</td>
<td>Announces</td>
<td>Sell</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Mark Lipacis</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$200.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Srini Pajjuri</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$150.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Harsh Kumar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Matt Bryson</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$160.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$150.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Joshua Buchalter</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$140.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$125.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Maintains</td>
<td>Positive</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$168.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$205.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$162.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Mark Lipacis</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Hans Mosesmann</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to NVIDIA. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of NVIDIA compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of NVIDIA's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of NVIDIA's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/NVDA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on NVIDIA analyst ratings.</a>
<h2>Delving into NVIDIA's Background</h2>
Nvidia is a leading developer of graphics processing units. Traditionally, GPUs were used to enhance the experience on computing platforms, most notably in gaming applications on PCs. GPU use cases have since emerged as important semiconductors used in artificial intelligence. Nvidia not only offers AI GPUs, but also a software platform, Cuda, used for AI model development and training. Nvidia is also expanding its data center networking solutions, helping to tie GPUs together to handle complex workloads.
<h3>Financial Insights: NVIDIA</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: NVIDIA displayed positive results in 3M. As of 31 January, 2025, the company achieved a solid revenue growth rate of approximately 77.94%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: NVIDIA's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 56.17% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 30.42%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): NVIDIA's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 21.28%, the company showcases efficient use of assets and strong financial health.
Debt Management: NVIDIA's debt-to-equity ratio is below the industry average. With a ratio of 0.13, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

NVDA

The Analyst Verdict: NVIDIA In The Eyes Of 37 Experts

15 analysts have shared their evaluations of Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $33.6, with a high estimate of $63.00 and a low estimate of $20.00. Highlighting a 23.39% decrease, the current average has fallen from the previous average price target of $43.86. 
<img src="https://www.benzinga.com/files/images/story/2025/1747951268_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Tandem Diabetes Care is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$59.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$31.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Neutral</td>
<td>$20.00</td>
<td>-</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$33.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$63.00</td>
<td>$63.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Tandem Diabetes Care. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Tandem Diabetes Care compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Tandem Diabetes Care's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Tandem Diabetes Care's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TNDM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Tandem Diabetes Care analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Tandem Diabetes Care</h2>
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
<h3>Key Indicators: Tandem Diabetes Care's Financial Health</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Tandem Diabetes Care displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 22.3%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -55.69%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Tandem Diabetes Care's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -62.41%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -13.82%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 3.18, caution is advised due to increased financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TNDM

Where Tandem Diabetes Care Stands With Analysts

Throughout the last three months, 8 analysts have evaluated Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Moderna, revealing an average target of $37.62, a high estimate of $70.00, and a low estimate of $26.00. Observing a downward trend, the current average is 16.94% lower than the prior average price target of $45.29. 
<img src="https://www.benzinga.com/files/images/story/2025/1747951259_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Moderna. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$26.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$70.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$40.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$28.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Cory Kasimov</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$32.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$32.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$33.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$40.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Moderna. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Moderna compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Moderna's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Moderna's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MRNA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Moderna analyst ratings.</a>
<h2>Get to Know Moderna Better</h2>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
<h3>Understanding the Numbers: Moderna's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Moderna's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -35.93%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Moderna's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -907.48%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Moderna's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -9.26%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Moderna's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -7.23%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Moderna's debt-to-equity ratio is below the industry average. With a ratio of 0.07, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MRNA

Where Moderna Stands With Analysts

IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) has outperformed the market over the past 5 years by 3.02% on an annualized basis producing an average annual return of 17.31%. Currently, IBM has a market capitalization of $240.71 billion. 
Buying $1000 In IBM: If an investor had bought $1000 of IBM stock 5 years ago, it would be worth $2,221.57 today based on a price of $259.00 for IBM at the time of writing.
<h3>IBM's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747951252_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In IBM 5 Years Ago Would Be Worth This Much Today

In the last three months, 4 analysts have published ratings on Vericel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCEL#NASDAQ">VCEL</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Vericel, presenting an average target of $59.75, a high estimate of $67.00, and a low estimate of $51.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 6.27%. 
<img src="https://www.benzinga.com/files/images/story/2025/1747951247_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Vericel. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$67.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$51.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$61.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Vericel. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Vericel compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Vericel's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Vericel's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VCEL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Vericel analyst ratings.</a>
<h2>Discovering Vericel: A Closer Look</h2>
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
<h3>A Deep Dive into Vericel's Financials</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Vericel's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 2.57%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Vericel's net margin is impressive, surpassing industry averages. With a net margin of -21.38%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Vericel's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -3.83%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Vericel's ROA excels beyond industry benchmarks, reaching -2.62%. This signifies efficient management of assets and strong financial health.
Debt Management: Vericel's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.33.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VCEL

What Analysts Are Saying About Vericel Stock

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on ZTO Express (Cayman) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTO#NYSE">ZTO</a>) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated ZTO Express (Cayman) and provided 12-month price targets. The average target is $21.65, accompanied by a high estimate of $23.00 and a low estimate of $19.00. A 13.85% drop is evident in the current average compared to the previous average price target of $25.13. 
<img src="https://www.benzinga.com/files/images/story/2025/1747951234_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of ZTO Express (Cayman)'s perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lu Xu</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.60</td>
<td>$26.40</td>
</tr>
<tr>
<td>Fan Tso</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Parash Jain</td>
<td>HSBC</td>
<td>Announces</td>
<td>Buy</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Lin Chen</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to ZTO Express (Cayman). This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ZTO Express (Cayman) compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for ZTO Express (Cayman)'s future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into ZTO Express (Cayman)'s market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ZTO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on ZTO Express (Cayman) analyst ratings.</a>
<h2>Unveiling the Story Behind ZTO Express (Cayman)</h2>
ZTO Express is China's largest express delivery company by parcel volume, with a volume share of 22.1% in 2022. It operates a network partner model where it provides line-haul transportation and sorting services, while its local network partners provide first-mile pickup and last-mile delivery services under the ZTO brand name. Headquartered in Shanghai, the company was founded in 2002 by Meisong Lai, who remains chair, CEO, and its major shareholder with 77% voting rights as of June 30, 2023. ZTO's strategic shareholder is leading China e-commerce company Alibaba Group with around an 11.7% interest.
<h3>A Deep Dive into ZTO Express (Cayman)'s Financials</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3M period, ZTO Express (Cayman) showcased positive performance, achieving a revenue growth rate of 21.66% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 19.61%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): ZTO Express (Cayman)'s ROE excels beyond industry benchmarks, reaching 4.13%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): ZTO Express (Cayman)'s financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.73%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.28.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where ZTO Express (Cayman) Stands With Analysts

In the current session, the stock is trading at $195.96, after a 2.19% spike. Over the past month, Taiwan Semiconductor Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) stock increased by 19.50%, and in the past year, by 22.62%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1747951224_0.png" alt="Past Year Chart" />

<h3>How Does Taiwan Semiconductor P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 153.45 in the Semiconductors &amp; Semiconductor Equipment industry, Taiwan Semiconductor Inc. has a lower P/E ratio of 23.19. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747951224_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Comments

Vivos

Vendite allo scoperto

Vivos (OTC:RDGL) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO